A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSEESCALATION STUDY OF THE SAFETY, TOLERABILITY AND ABILITY OF CMX001 TO PREVENT OR CONTROL CMV INFECTION IN R+ HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
|Effective start/end date||11/17/09 → 9/29/12|
- Chimerix, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.